Gambling, Resorts & Casinos
Compare Stocks
5 / 10Stock Comparison
BRSL vs FLUT vs DKNG vs GENI vs SRAD
Revenue, margins, valuation, and 5-year total return — side by side.
Gambling, Resorts & Casinos
Gambling, Resorts & Casinos
Internet Content & Information
Software - Application
BRSL vs FLUT vs DKNG vs GENI vs SRAD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Gambling, Resorts & Casinos | Gambling, Resorts & Casinos | Gambling, Resorts & Casinos | Internet Content & Information | Software - Application |
| Market Cap | $2.35B | $17.64B | $12.50B | $1.17B | $4.04B |
| Revenue (TTM) | $2.51B | $17.02B | $6.05B | $669M | $1.33B |
| Net Income (TTM) | $147M | $-455M | $4M | $-112M | $70M |
| Gross Margin | 47.1% | 44.2% | 41.3% | 22.9% | 38.2% |
| Operating Margin | 29.8% | 4.4% | -0.2% | -18.1% | 9.3% |
| Forward P/E | 14.7x | 16.5x | 99.1x | 52.4x | 33.1x |
| Total Debt | $4.25B | $13.35B | $1.93B | $30M | $63M |
| Cash & Equiv. | $1.45B | $3.83B | $1.60B | $281M | $365M |
BRSL vs FLUT vs DKNG vs GENI vs SRAD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 21 | May 26 | Return |
|---|---|---|---|
| Brightstar Lottery (BRSL) | 100 | 48.2 | -51.8% |
| Flutter Entertainme… (FLUT) | 100 | 51.1 | -48.9% |
| DraftKings Inc. (DKNG) | 100 | 52.4 | -47.6% |
| Genius Sports Limit… (GENI) | 100 | 25.5 | -74.5% |
| Sportradar Group AG (SRAD) | 100 | 60.3 | -39.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BRSL vs FLUT vs DKNG vs GENI vs SRAD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BRSL carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 2 yrs, beta 0.91, yield 30.8%
- 31.3% 10Y total return vs DKNG's 157.3%
- Lower P/E (14.7x vs 52.4x)
- 5.9% margin vs GENI's -16.7%
FLUT lags the leaders in this set but could rank higher in a more targeted comparison.
DKNG is the clearest fit if your priority is growth exposure.
- Rev growth 27.0%, EPS growth 99.2%, 3Y rev CAGR 39.3%
GENI ranks third and is worth considering specifically for growth.
- 31.0% revenue growth vs BRSL's -0.0%
SRAD is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.
- Lower volatility, beta 0.65, Low D/E 6.4%, current ratio 1.17x
- Beta 0.65, current ratio 1.17x
- Beta 0.65 vs GENI's 1.50
- 2.7% ROA vs GENI's -11.1%, ROIC 12.9% vs -16.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 31.0% revenue growth vs BRSL's -0.0% | |
| Value | Lower P/E (14.7x vs 52.4x) | |
| Quality / Margins | 5.9% margin vs GENI's -16.7% | |
| Stability / Safety | Beta 0.65 vs GENI's 1.50 | |
| Dividends | 30.8% yield; 2-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | -2.4% vs FLUT's -58.3% | |
| Efficiency (ROA) | 2.7% ROA vs GENI's -11.1%, ROIC 12.9% vs -16.6% |
BRSL vs FLUT vs DKNG vs GENI vs SRAD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
BRSL vs FLUT vs DKNG vs GENI vs SRAD — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
BRSL leads in 4 of 6 categories
FLUT leads 0 • DKNG leads 0 • GENI leads 0 • SRAD leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
BRSL leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
FLUT is the larger business by revenue, generating $17.0B annually — 25.4x GENI's $669M. BRSL is the more profitable business, keeping 5.9% of every revenue dollar as net income compared to GENI's -16.7%. On growth, DKNG holds the edge at +42.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2.5B | $17.0B | $6.1B | $669M | $1.3B |
| EBITDAEarnings before interest/tax | $1.1B | $2.0B | $266M | -$50M | $308M |
| Net IncomeAfter-tax profit | $147M | -$455M | $4M | -$112M | $70M |
| Free Cash FlowCash after capex | -$456M | $880M | $612M | $37M | $363M |
| Gross MarginGross profit ÷ Revenue | +47.1% | +44.2% | +41.3% | +22.9% | +38.2% |
| Operating MarginEBIT ÷ Revenue | +29.8% | +4.4% | -0.2% | -18.1% | +9.3% |
| Net MarginNet income ÷ Revenue | +5.9% | -2.7% | +0.1% | -16.7% | +5.2% |
| FCF MarginFCF ÷ Revenue | -18.2% | +5.2% | +10.1% | +5.5% | +27.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.5% | +17.4% | +42.8% | +37.0% | +13.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -70.1% | -22.3% | +192.9% | +33.8% | -128.5% |
Valuation Metrics
BRSL leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, BRSL's 4.7x EV/EBITDA is more attractive than DKNG's 49.4x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $2.3B | $17.6B | $12.5B | $1.2B | $4.0B |
| Enterprise ValueMkt cap + debt − cash | $5.2B | $27.2B | $12.8B | $924M | $3.7B |
| Trailing P/EPrice ÷ TTM EPS | -1269.00x | -58.47x | -3113.58x | -10.83x | 38.69x |
| Forward P/EPrice ÷ next-FY EPS est. | 14.65x | 16.51x | 99.14x | 52.42x | 33.09x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 0.68x |
| EV / EBITDAEnterprise value multiple | 4.67x | 10.69x | 49.42x | — | 17.74x |
| Price / SalesMarket cap ÷ Revenue | 0.94x | 1.08x | 2.06x | 1.75x | 2.77x |
| Price / BookPrice ÷ Book value/share | 1.57x | 1.87x | 19.81x | 1.68x | 3.79x |
| Price / FCFMarket cap ÷ FCF | — | 16.35x | 19.31x | 18.18x | 8.98x |
Profitability & Efficiency
Evenly matched — BRSL and SRAD each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
BRSL delivers a 9.2% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-16 for GENI. GENI carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to DKNG's 3.06x. On the Piotroski fundamental quality scale (0–9), DKNG scores 7/9 vs GENI's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +9.2% | -4.3% | +0.5% | -15.5% | +7.3% |
| ROA (TTM)Return on assets | +1.6% | -1.6% | +0.1% | -11.1% | +2.7% |
| ROICReturn on invested capital | +11.7% | +4.5% | -0.9% | -16.6% | +12.9% |
| ROCEReturn on capital employed | +12.9% | +4.6% | -0.6% | -15.3% | +5.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 | 7 | 3 | 4 |
| Debt / EquityFinancial leverage | 2.67x | 1.38x | 3.06x | 0.04x | 0.06x |
| Net DebtTotal debt minus cash | $2.8B | $9.5B | $330M | -$250M | -$302M |
| Cash & Equiv.Liquid assets | $1.4B | $3.8B | $1.6B | $281M | $365M |
| Total DebtShort + long-term debt | $4.3B | $13.3B | $1.9B | $30M | $63M |
| Interest CoverageEBIT ÷ Interest expense | 3.66x | 0.04x | 1.92x | -136.57x | 2.02x |
Total Returns (Dividends Reinvested)
BRSL leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BRSL five years ago would be worth $10,703 today (with dividends reinvested), compared to $2,536 for GENI. Over the past 12 months, BRSL leads with a -2.4% total return vs FLUT's -58.3%. The 3-year compound annual growth rate (CAGR) favors GENI at 5.5% vs FLUT's -20.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -15.6% | -53.7% | -29.3% | -55.8% | -41.5% |
| 1-Year ReturnPast 12 months | -2.4% | -58.3% | -27.3% | -53.1% | -41.4% |
| 3-Year ReturnCumulative with dividends | -33.8% | -49.0% | +4.3% | +17.4% | +5.7% |
| 5-Year ReturnCumulative with dividends | +7.0% | -50.7% | -47.9% | -74.6% | -45.5% |
| 10-Year ReturnCumulative with dividends | +31.3% | -22.9% | +157.3% | -52.4% | -45.5% |
| CAGR (3Y)Annualised 3-year return | -12.8% | -20.1% | +1.4% | +5.5% | +1.9% |
Risk & Volatility
Evenly matched — BRSL and SRAD each lead in 1 of 2 comparable metrics.
Risk & Volatility
SRAD is the less volatile stock with a 0.65 beta — it tends to amplify market swings less than GENI's 1.50 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BRSL currently trades 68.3% from its 52-week high vs FLUT's 32.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.91x | 1.23x | 1.12x | 1.50x | 0.65x |
| 52-Week HighHighest price in past year | $18.57 | $313.69 | $48.78 | $13.73 | $32.22 |
| 52-Week LowLowest price in past year | $12.02 | $97.94 | $20.46 | $3.83 | $11.66 |
| % of 52W HighCurrent price vs 52-week peak | +68.3% | +32.2% | +51.7% | +34.7% | +42.3% |
| RSI (14)Momentum oscillator 0–100 | 47.1 | 35.0 | 55.1 | 45.3 | 38.7 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 3.4M | 12.9M | 5.6M | 3.6M |
Analyst Outlook
BRSL leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: BRSL as "Buy", FLUT as "Buy", DKNG as "Buy", GENI as "Buy", SRAD as "Buy". Consensus price targets imply 153.9% upside for GENI (target: $12) vs 45.8% for BRSL (target: $19). BRSL is the only dividend payer here at 30.80% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $18.50 | $227.86 | $36.88 | $12.10 | $21.75 |
| # AnalystsCovering analysts | 6 | 24 | 48 | 19 | 20 |
| Dividend YieldAnnual dividend ÷ price | +30.8% | — | — | — | — |
| Dividend StreakConsecutive years of raises | 2 | 1 | — | 1 | — |
| Dividend / ShareAnnual DPS | $3.91 | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +11.5% | +6.4% | +6.6% | 0.0% | +2.9% |
BRSL leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 2 categories are tied.
BRSL vs FLUT vs DKNG vs GENI vs SRAD: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is BRSL or FLUT or DKNG or GENI or SRAD a better buy right now?
For growth investors, Genius Sports Limited (GENI) is the stronger pick with 31.
0% revenue growth year-over-year, versus -0. 0% for Brightstar Lottery (BRSL). Sportradar Group AG (SRAD) offers the better valuation at 38. 7x trailing P/E (33. 1x forward), making it the more compelling value choice. Analysts rate Brightstar Lottery (BRSL) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BRSL or FLUT or DKNG or GENI or SRAD?
On forward P/E, Brightstar Lottery is actually cheaper at 14.
7x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — BRSL or FLUT or DKNG or GENI or SRAD?
Over the past 5 years, Brightstar Lottery (BRSL) delivered a total return of +7.
0%, compared to -74. 6% for Genius Sports Limited (GENI). Over 10 years, the gap is even starker: DKNG returned +157. 3% versus GENI's -52. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BRSL or FLUT or DKNG or GENI or SRAD?
By beta (market sensitivity over 5 years), Sportradar Group AG (SRAD) is the lower-risk stock at 0.
65β versus Genius Sports Limited's 1. 50β — meaning GENI is approximately 130% more volatile than SRAD relative to the S&P 500. On balance sheet safety, Genius Sports Limited (GENI) carries a lower debt/equity ratio of 4% versus 3% for DraftKings Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — BRSL or FLUT or DKNG or GENI or SRAD?
By revenue growth (latest reported year), Genius Sports Limited (GENI) is pulling ahead at 31.
0% versus -0. 0% for Brightstar Lottery (BRSL). On earnings-per-share growth, the picture is similar: Sportradar Group AG grew EPS 200. 0% year-over-year, compared to -820. 8% for Flutter Entertainment plc. Over a 3-year CAGR, DKNG leads at 39. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — BRSL or FLUT or DKNG or GENI or SRAD?
Sportradar Group AG (SRAD) is the more profitable company, earning 7.
8% net margin versus -16. 7% for Genius Sports Limited — meaning it keeps 7. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BRSL leads at 35. 1% versus -15. 6% for GENI. At the gross margin level — before operating expenses — FLUT leads at 45. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is BRSL or FLUT or DKNG or GENI or SRAD more undervalued right now?
On forward earnings alone, Brightstar Lottery (BRSL) trades at 14.
7x forward P/E versus 99. 1x for DraftKings Inc. — 84. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GENI: 153. 9% to $12. 10.
08Which pays a better dividend — BRSL or FLUT or DKNG or GENI or SRAD?
In this comparison, BRSL (30.
8% yield) pays a dividend. FLUT, DKNG, GENI, SRAD do not pay a meaningful dividend and should not be held primarily for income.
09Is BRSL or FLUT or DKNG or GENI or SRAD better for a retirement portfolio?
For long-horizon retirement investors, Brightstar Lottery (BRSL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
91), 30. 8% yield). Genius Sports Limited (GENI) carries a higher beta of 1. 50 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BRSL: +31. 3%, GENI: -52. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between BRSL and FLUT and DKNG and GENI and SRAD?
These companies operate in different sectors (BRSL (Consumer Cyclical) and FLUT (Consumer Cyclical) and DKNG (Consumer Cyclical) and GENI (Communication Services) and SRAD (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: BRSL is a small-cap income-oriented stock; FLUT is a mid-cap high-growth stock; DKNG is a mid-cap high-growth stock; GENI is a small-cap high-growth stock; SRAD is a small-cap quality compounder stock. BRSL pays a dividend while FLUT, DKNG, GENI, SRAD do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
- Sector: Communication Services
- Market Cap > $100B
- Revenue Growth > 18%
- Gross Margin > 13%
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.